Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1626551rdf:typepubmed:Citationlld:pubmed
pubmed-article:1626551lifeskim:mentionsumls-concept:C0022661lld:lifeskim
pubmed-article:1626551lifeskim:mentionsumls-concept:C0016884lld:lifeskim
pubmed-article:1626551lifeskim:mentionsumls-concept:C2728259lld:lifeskim
pubmed-article:1626551pubmed:issue1 Suppl 1lld:pubmed
pubmed-article:1626551pubmed:dateCreated1992-8-7lld:pubmed
pubmed-article:1626551pubmed:abstractTextThe rapidly changing health care environment in the United States will affect the future of nephrology in several areas. Reductions in Medicare spending will affect graduate medical education, physician payments, and, eventually, payments for medical supplies and therapeutic agents. The resource-based relative value system (RBRVS) developed by the Health Care Financing Administration (HCFA) will be implemented over the next 4 years, and it is likely that similar plans will be adopted by other insurance carriers. Under this system, payments for the procedure of dialysis will be substantially reduced--decreases in Medicare reimbursement will range from approximately 30% to 60% depending on geographic location and current charges. However, the current economic pressures may have a beneficial effect on the practice of nephrology by providing an incentive to develop standardized practice guidelines that will eliminate wide variations in practices and minimize unfounded litigation. In the near future, attention must also focus on the training of nephrology fellows; ideas for future directions are presented.lld:pubmed
pubmed-article:1626551pubmed:languageenglld:pubmed
pubmed-article:1626551pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1626551pubmed:citationSubsetIMlld:pubmed
pubmed-article:1626551pubmed:statusMEDLINElld:pubmed
pubmed-article:1626551pubmed:monthJullld:pubmed
pubmed-article:1626551pubmed:issn0272-6386lld:pubmed
pubmed-article:1626551pubmed:authorpubmed-author:PaganiniE PEPlld:pubmed
pubmed-article:1626551pubmed:issnTypePrintlld:pubmed
pubmed-article:1626551pubmed:volume20lld:pubmed
pubmed-article:1626551pubmed:ownerNLMlld:pubmed
pubmed-article:1626551pubmed:authorsCompleteYlld:pubmed
pubmed-article:1626551pubmed:pagination12-5lld:pubmed
pubmed-article:1626551pubmed:dateRevised2005-11-16lld:pubmed
pubmed-article:1626551pubmed:meshHeadingpubmed-meshheading:1626551-...lld:pubmed
pubmed-article:1626551pubmed:meshHeadingpubmed-meshheading:1626551-...lld:pubmed
pubmed-article:1626551pubmed:meshHeadingpubmed-meshheading:1626551-...lld:pubmed
pubmed-article:1626551pubmed:meshHeadingpubmed-meshheading:1626551-...lld:pubmed
pubmed-article:1626551pubmed:meshHeadingpubmed-meshheading:1626551-...lld:pubmed
pubmed-article:1626551pubmed:meshHeadingpubmed-meshheading:1626551-...lld:pubmed
pubmed-article:1626551pubmed:year1992lld:pubmed
pubmed-article:1626551pubmed:articleTitleThe future of the end-stage renal disease program.lld:pubmed
pubmed-article:1626551pubmed:affiliationDepartment of Hypertension/Nephrology, Cleveland Clinic Foundation, OH 44106.lld:pubmed
pubmed-article:1626551pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1626551pubmed:publicationTypeReviewlld:pubmed